Print
|
Close
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Active:
No
Cancer Type:
Prostate Cancer
Unknown Primary
NCT ID:
NCT05022849
Trial Phases:
Phase I
Protocol IDs:
CR108972 (primary)
NCI-2021-12359
75229414MPC1001
Eligibility:
18 Years and older, Male
Study Type:
Other
Study Sponsor:
Janssen Research & Development, LLC
NCI Full Details:
http://clinicaltrials.gov/show/NCT05022849
Summary
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of
JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in
Part 2 (Dose Expansion).
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.